

**OncoBeta® GmbH**  
Lichtenbergstr. 8  
85748 Garching n. Munich  
GERMANY

## **First Non-Melanocytic Skin Cancer Patients treated with Rhenium-SCT® in Australia**

### **Rhenium-SCT® a Non-Invasive, Painless Treatment for Non-Melanocytic Skin Cancer Patients now offered in Australia**

#### **FOR IMMEDIATE RELEASE**

November 23, 2018

**Garching n. Munich, Germany, (November 23, 2018)** - OncoBeta® GmbH a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today that Dr. Joe Cardaci from the Hollywood Private Hospital has treated the first NMSC patient in Perth Australia with the innovative Rhenium-SCT® (skin cancer treatment) System. This next-generation radionuclide therapy technology applied by the nuclear medicine physician offers a new singles session, painless treatment for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs). The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Approximately 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas with Australia having one of the world’s highest incidence rates.

Dr. Joe Cardaci from the Hollywood Private Hospital is focused on providing patients with personalized, non-invasive care using state-of-the-art technology that can deliver high-precision treatment with minimal side effects. This includes General nuclear medicine, Functional Brain Imaging and Radionuclide therapy now with the Rhenium-SCT®. His specialized team in the nuclear medicine works closely with other disciplines within the hospital, referring physicians, and other institutions, to ensure patients receive the best possible treatment for their specific illness.

The Rhenium-SCT® (Skin Cancer Therapy) is being offered though OncoBeta’s Australian affiliate OncoBeta® Therapeutics Pty Ltd. for private clinics until the TGA application has been processed making it then broadly available for the world’s largest population of Non-Melanocytic Skin Cancers.

“We are extremely delighted and proud to be able to offer our revolutionary treatment to patients in Australia now, one of countries the highest rates of affected people" said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "Our highly qualified team is dedicated to bring physicians and patients a non-invasive and affordable non-melanoma skin cancer therapy solution”.

#### **About the Rhenium-SCT® (Skin Cancer Therapy)**

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single

application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

### **About OncoBeta® GmbH**

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.

Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

Find out more about the Rhenium-SCT® at [www.oncobeta.com](http://www.oncobeta.com)

### **Follow us on social media:**

LinkedIn: <https://www.linkedin.com/company/oncobeta-gmbh/>

### **Forward-looking statements**

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.